Engineered probiotics for the control of antibiotic-resistant and difficult-to-treat pathogens
Abstract
The increasing prevalence of antibiotic-resistant pathogens and recurrent, biofilm-associated, toxin-mediated, or dysbiosis-related infections has created an urgent need for strategies that complement conventional antibiotics. Broad-spectrum therapy can disrupt commensal microbiota, weaken colonization resistance, and promote opportunistic or recurrent infection. Engineered probiotics offer microbiology-based interventions that can inhibit pathogen growth, disrupt biofilms, attenuate virulence, neutralize toxins, and restore protective microbiota functions. Engineered probiotic and commensal microorganisms can also respond to pathogen- or infection-associated signals, improving therapeutic localization and specificity. This review summarizes strategies for controlling antibiotic-resistant and difficult-to-treat pathogens, including pathogen-responsive antimicrobial production, bacteriocin-, pyocin-, lysin-, and antimicrobial peptide-mediated inhibition, enzymatic biofilm degradation, anti-virulence and toxin-neutralization approaches, restoration of microbiota-mediated colonization resistance, and targeted genetic approaches for pathogen elimination or antibiotic resensitization. Representative systems against Pseudomonas aeruginosa , Clostridioides difficile , Staphylococcus aureus , Listeria monocytogenes , Streptococcus pyogenes , and resistant Enterobacteriaceae are discussed. Major translational challenges include chassis selection, genetic stability, horizontal gene transfer, biocontainment, delivery, manufacturing, regulation, and host-microbiota variability. Engineered probiotics may therefore provide selective, localized, and microbiota-preserving complements to conventional therapy.